{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T04:47:03Z","timestamp":1783745223360,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,3,27]],"date-time":"2018-03-27T00:00:00Z","timestamp":1522108800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670611"],"award-info":[{"award-number":["81670611"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"crossref","award":["2016YFC0901500"],"award-info":[{"award-number":["2016YFC0901500"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100008272","name":"Novartis Pharmaceuticals Corporation","doi-asserted-by":"publisher","award":["I10288"],"award-info":[{"award-number":["I10288"]}],"id":[{"id":"10.13039\/100008272","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13023-018-0781-y","type":"journal-article","created":{"date-parts":[[2018,4,4]],"date-time":"2018-04-04T04:19:30Z","timestamp":1522815570000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Assessing the outcomes of everolimus on renal angiomyolipoma associated with tuberous sclerosis complex in China: a two years trial"],"prefix":"10.1186","volume":"13","author":[{"given":"Yi","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenda","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanzhong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yushi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,3,27]]},"reference":[{"issue":"4","key":"781_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","volume":"49","author":"H Northrup","year":"2013","unstructured":"Northrup H, Krueger DA. Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 Iinternational tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49(4):243\u201354.","journal-title":"Pediatr Neurol"},{"key":"781_CR2","doi-asserted-by":"publisher","first-page":"170.e1","DOI":"10.1016\/j.urology.2016.10.056","volume":"101","author":"Y Cai","year":"2017","unstructured":"Cai Y, Li H, Zhang Y. Assessment of tuberous sclerosis complex associated with renal lesions by targeted next-generation sequencing in mainland China. Urology. 2017;101:170.e1\u20137.","journal-title":"Urology"},{"key":"781_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.urology.2015.12.009","volume":"89","author":"A Kapoor","year":"2016","unstructured":"Kapoor A, et al. Evolving strategies in the treatment of tuberous sclerosis complex-associated Angiomyolipomas (TSC-AML). Urology. 2016;89:19\u201326.","journal-title":"Urology"},{"issue":"26","key":"781_CR4","first-page":"2056","volume":"93","author":"WY Ting","year":"2013","unstructured":"Ting WY, et al. Clinical analysis of tuberous sclerosis complex complicated with renal angiomyolipoma: a report of 22 cases. Zhonghua Yi Xue Za Zhi. 2013;93(26):2056\u20138.","journal-title":"Zhonghua Yi Xue Za Zhi"},{"issue":"7","key":"781_CR5","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/0092-8674(93)90618-Z","volume":"75","author":"ECTS Consortium","year":"1993","unstructured":"Consortium ECTS. Identification and characterization of the tuberous sclerosis gene on chromosome 16. Cell. 1993;75(7):1305\u201315.","journal-title":"Cell"},{"issue":"5327","key":"781_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1126\/science.277.5327.805","volume":"277","author":"M van Slegtenhorst","year":"1997","unstructured":"van Slegtenhorst M, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. Science. 1997;277(5327):805\u20138.","journal-title":"Science"},{"issue":"2","key":"781_CR7","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","volume":"149","author":"M Laplante","year":"2012","unstructured":"Laplante M, Sabatini DM. mTOR signaling in growth control and disease. Cell. 2012;149(2):274\u201393.","journal-title":"Cell"},{"issue":"9869","key":"781_CR8","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/S0140-6736(12)61767-X","volume":"381","author":"JJ Bissler","year":"2013","unstructured":"Bissler JJ, et al. Everolimus for angiomyolipoma associated with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis (EXIST-2): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2013;381(9869):817\u201324.","journal-title":"Lancet"},{"issue":"4","key":"781_CR9","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.pediatrneurol.2013.08.002","volume":"49","author":"DA Krueger","year":"2013","unstructured":"Krueger DA, Northrup H. Tuberous sclerosis complex surveillance and management: recommendations of the 2012 international tuberous sclerosis complex consensus conference. Pediatr Neurol. 2013;49(4):255\u201365.","journal-title":"Pediatr Neurol"},{"issue":"5","key":"781_CR10","first-page":"581","volume":"137","author":"M Duvic","year":"2001","unstructured":"Duvic M, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001;137(5):581\u201393.","journal-title":"Arch Dermatol"},{"issue":"5","key":"781_CR11","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/S0190-9622(03)01475-0","volume":"49","author":"P Heald","year":"2003","unstructured":"Heald P, et al. Topical bexarotene therapy for patients with refractory or persistent early-stage cutaneous T-cell lymphoma: results of the phase III clinical trial. J Am Acad Dermatol. 2003;49(5):801\u201315.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"781_CR12","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1038\/ncb847","volume":"4","author":"X Gao","year":"2002","unstructured":"Gao X, et al. Tsc tumour suppressor proteins antagonize amino-acid-TOR signalling. Nat Cell Biol. 2002;4(9):699\u2013704.","journal-title":"Nat Cell Biol"},{"issue":"21","key":"781_CR13","doi-asserted-by":"publisher","first-page":"13571","DOI":"10.1073\/pnas.202476899","volume":"99","author":"AR Tee","year":"2002","unstructured":"Tee AR, et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. Proc Natl Acad Sci U S A. 2002;99(21):13571\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10056","key":"781_CR14","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","volume":"388","author":"JA French","year":"2016","unstructured":"French JA, et al. Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study. Lancet. 2016;388(10056):2153\u201363.","journal-title":"Lancet"},{"issue":"9861","key":"781_CR15","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","volume":"381","author":"DN Franz","year":"2013","unstructured":"Franz DN, et al. Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2013;381(9861):125\u201332.","journal-title":"Lancet"},{"issue":"1","key":"781_CR16","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/ndt\/gfv249","volume":"31","author":"JJ Bissler","year":"2016","unstructured":"Bissler JJ, et al. Everolimus for renal angiomyolipoma in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis: extension of a randomized controlled trial. Nephrol Dial Transplant. 2016;31(1):111\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"781_CR17","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1093\/ndt\/gfu013","volume":"29","author":"JC Kingswood","year":"2014","unstructured":"Kingswood JC, et al. The effect of everolimus on renal angiomyolipoma in patients with tuberous sclerosis complex being treated for subependymal giant cell astrocytoma: subgroup results from the randomized, placebo-controlled, phase 3 trial EXIST-1. Nephrol Dial Transplant. 2014;29(6):1203\u201310.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"781_CR18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa063564","volume":"358","author":"JJ Bissler","year":"2008","unstructured":"Bissler JJ, et al. Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis. N Engl J Med. 2008;358(2):140\u201351.","journal-title":"N Engl J Med"},{"issue":"8","key":"781_CR19","doi-asserted-by":"publisher","first-page":"e0180939","DOI":"10.1371\/journal.pone.0180939","volume":"12","author":"JJ Bissler","year":"2017","unstructured":"Bissler JJ, et al. Everolimus long-term use in patients with tuberous sclerosis complex: four-year update of the EXIST-2 study. PLoS One. 2017;12(8):e0180939.","journal-title":"PLoS One"},{"issue":"5","key":"781_CR20","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.eururo.2005.11.035","volume":"49","author":"A Lopez-Beltran","year":"2006","unstructured":"Lopez-Beltran A, et al. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49(5):798\u2013805.","journal-title":"Eur Urol"},{"issue":"3","key":"781_CR21","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1016\/j.juro.2008.05.041","volume":"180","author":"BR Lane","year":"2008","unstructured":"Lane BR, et al. Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid. J Urol. 2008;180(3):836\u201343.","journal-title":"J Urol"},{"issue":"3","key":"781_CR22","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/path.2289","volume":"214","author":"CC Pan","year":"2008","unstructured":"Pan CC, et al. Constant allelic alteration on chromosome 16p (TSC2 gene) in perivascular epithelioid cell tumour (PEComa): genetic evidence for the relationship of PEComa with angiomyolipoma. J Pathol. 2008;214(3):387\u201393.","journal-title":"J Pathol"},{"issue":"5","key":"781_CR23","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1200\/JCO.2009.26.3061","volume":"28","author":"N Wolff","year":"2010","unstructured":"Wolff N, et al. Sirolimus and temsirolimus for epithelioid angiomyolipoma. J Clin Oncol. 2010;28(5):e65\u20138.","journal-title":"J Clin Oncol"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0781-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13023-018-0781-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0781-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,19]],"date-time":"2020-05-19T06:58:52Z","timestamp":1589871532000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-018-0781-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3,27]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["781"],"URL":"https:\/\/doi.org\/10.1186\/s13023-018-0781-y","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3,27]]},"assertion":[{"value":"13 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients provided written informed consent before entering the clinical trial. The study was done in accordance with the Declaration of Helsinki and local regulations This study protocol was approved by the Human Ethics Committee of Peking Union Medical College Hospital, before the first patient was enrolled.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Yi Cai received travel expenses from Novartis CO., LTD. The other authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"43"}}